Loading
Journal

Journal

GU Oncology Now Journal
Akhil Abraham Saji, MD

Journal | August 24, 2022

Rectal spacing technology can reduce radiation exposure to nontarget organs, which decreases toxicity.

Akhil Abraham Saji, MD

Journal | August 24, 2022

A review of a series of articles published by Urology on diversity, equity, and inclusion findings in prostate cancer care.

David Ambinder, MD

Journal | August 24, 2022

Studies on the use of cytoreductive nephrectomy in mRCC are reviewed, including its role among TKIs and immunotherapy.

Daniel Tennenbaum, MD

Journal | August 24, 2022

A report examines the correlation between family history of prostate cancer and risk of progression after prostatectomy.

David Ambinder, MD

Journal | August 24, 2022

Dr. Stacy Loeb is interviewed on the use of active surveillance for prostate cancer, its history, and new insights.

Linda Brookes, MSc

Journal | August 24, 2022

Catherine Handy Marshall reviews her career from cardiovascular disease research to prostate cancer risk factors & genetics.

David Ambinder, MD

Journal | August 24, 2022

The utility of using AI to help determine scoring and surgical options for kidney cancer is examined against human scoring.

Akhil Abraham Saji, MD

Journal | August 24, 2022

18F-based PSMA imaging can provide greater spatial resolution as well as detect lesions not picked up by 68Ga-PSMA-11.

Catherine H. Marshall, MD, MPH

Journal | August 24, 2022

Dr Catherine Handy Marshall gives prostate cancer patients care advice beyond appointments and medical interventions.

Akhil Abraham Saji, MD

Journal | July 27, 2022

The role of 3D modeling in the treatment of renal tumors is discussed, including developments in the technology.

GU Oncology Now Editors

Journal | July 27, 2022

Prostate cancer highlights from ASCO 2022 are discussed, including the ENZAMET trial design and TheraP trial data.

David Ambinder, MD

Journal | July 27, 2022

The current standard of care for patients with high-grade NMIBC, intravesical Bacillus Calmette-Guérin, is discussed.

Catherine H. Marshall, MD, MPH

Journal | July 27, 2022

Highlights from ASCO 2022, including the role of doublet therapy (ADT combined with a novel oral antiandrogen drug).

Linda Brookes, MSc

Journal | July 27, 2022

Michael J. Morris, MD, gives insight into his history with prostate cancer clinical research and his role in clinical trials.

David Ambinder, MD

Journal | July 27, 2022

Benjamin Davies, MD, gives his insight on how to reduce the use of opiates for patients after urologic surgery.

Akhil Abraham Saji, MD

Journal | July 27, 2022

Plenary highlights from AUA 2022, including non-muscle invasive bladder cancer treatments and the SPOTLIGHT study.

David Ambinder, MD

Journal | July 27, 2022

Active surveillance and enzalutamide monotherapy for localized prostate cancer is compared with active surveillance alone.

Daniel Tennenbaum, MD

Journal | July 27, 2022

The standard of care transurethral resection for bladder tumors is compared with en bloc resections for urologic procedures.

David Ambinder, MD

Journal | June 24, 2022

Reviewing a JAMA report on the effect of robot-assisted radical cystectomy in bladder cancer, along with the RAZOR trial.

David Ambinder, MD

Journal | June 24, 2022

An analysis of the HERO trial discussing the safety of relugolix, including major adverse cardiovascular events.